Discounted Cash Flow (DCF) Analysis Unlevered
China Health Industries Holdings, I... (CHHE)
$0.14
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 6.55 | 9.28 | 9.93 | 6.49 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | 0.66 | 5.51 | 5.82 | 3.04 | 0.64 | 0.10 | 0.08 | 0.06 | 0.05 | 0.04 |
| EBITDA (%) | ||||||||||
| EBIT | -0 | 4.69 | 5.02 | 2.16 | -0.19 | -0.03 | -0.02 | -0.02 | -0.01 | -0.01 |
| EBIT (%) | ||||||||||
| Depreciation | 0.67 | 0.82 | 0.81 | 0.88 | 0.83 | 0.13 | 0.10 | 0.08 | 0.06 | 0.05 |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Total Cash | 32.61 | 35.51 | 36.07 | 44.35 | 44.79 | 7.03 | 5.52 | 4.33 | 3.40 | 2.67 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | 1.49 | 2.02 | 4.66 | 2.38 | 0.04 | 0.01 | 0.01 | 0 | 0 | 0 |
| Account Receivables (%) | ||||||||||
| Inventories | 0.45 | 0.86 | 0.81 | 0.76 | 0.52 | 0.08 | 0.06 | 0.05 | 0.04 | 0.03 |
| Inventories (%) | ||||||||||
| Accounts Payable | 0.40 | 0.50 | 0.41 | 0.41 | 0.33 | 0.05 | 0.04 | 0.03 | 0.03 | 0.02 |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | -0.41 | -0.15 | -0.16 | -0.01 | -0 | -0 | -0 | -0 | -0 | -0 |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.14 |
|---|---|
| Beta | -9.431 |
| Diluted Shares Outstanding | 65.54 |
| Cost of Debt | |
| Tax Rate | -0.84 |
| After-tax Cost of Debt | 2.32% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | -40.732 |
| Total Debt | 6.76 |
| Total Equity | 9.18 |
| Total Capital | 15.94 |
| Debt Weighting | 42.42 |
| Equity Weighting | 57.58 |
| Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 6.55 | 9.28 | 9.93 | 6.49 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | 0.66 | 5.51 | 5.82 | 3.04 | 0.64 | 0.10 | 0.08 | 0.06 | 0.05 | 0.04 |
| EBIT | -0 | 4.69 | 5.02 | 2.16 | -0.19 | -0.03 | -0.02 | -0.02 | -0.01 | -0.01 |
| Tax Rate | -489.31% | 29.50% | 29.23% | 36.13% | -0.84% | -79.06% | -79.06% | -79.06% | -79.06% | -79.06% |
| EBIAT | -0.03 | 3.31 | 3.55 | 1.38 | -0.20 | -0.05 | -0.04 | -0.03 | -0.03 | -0.02 |
| Depreciation | 0.67 | 0.82 | 0.81 | 0.88 | 0.83 | 0.13 | 0.10 | 0.08 | 0.06 | 0.05 |
| Accounts Receivable | - | -0.53 | -2.65 | 2.28 | 2.34 | 0.03 | 0 | 0 | 0 | 0 |
| Inventories | - | -0.40 | 0.05 | 0.05 | 0.24 | 0.44 | 0.02 | 0.01 | 0.01 | 0.01 |
| Accounts Payable | - | 0.10 | -0.09 | 0 | -0.07 | -0.28 | -0.01 | -0.01 | -0.01 | -0.01 |
| Capital Expenditure | -0.41 | -0.15 | -0.16 | -0.01 | -0 | -0 | -0 | -0 | -0 | -0 |
| UFCF | 0.24 | 3.13 | 1.51 | 4.57 | 3.14 | 0.27 | 0.07 | 0.05 | 0.04 | 0.03 |
| WACC | ||||||||||
| PV UFCF | 0.35 | 0.11 | 0.11 | 0.11 | 0.12 | |||||
| SUM PV UFCF | 0.80 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | -22.47 |
| Free cash flow (t + 1) | 0.03 |
| Terminal Value | -0.14 |
| Present Value of Terminal Value | -0.48 |
Intrinsic Value
| Enterprise Value | 0.32 |
|---|---|
| Net Debt | -38.03 |
| Equity Value | 38.35 |
| Shares Outstanding | 65.54 |
| Equity Value Per Share | 0.59 |